Eurostars: Companies and Institutions experienced in antimicrobial and resistance mechanisms sought to develop multifunctional biodegradable nanocapsules against bacterial diseases.

REQUEST from Spain, reference: RDES20190328002, valid from 28-03-2019 untill 31-05-2019

Research & Development
  • Start date:
    28 maart 2019 (4 weken geleden)
  • End date:
    31 mei 2019
  • Summary:
    Spanish SME experienced in the development and manufacturing of biodegradable polyurethane micro and nanocapsules is preparing a Eurostars proposal. The aim is to develop multifunctional biodegradable nanocapsules against bacterial diseases. Research partners with a deep understanding of antimicrobial drugs and their resistance mechanisms are sought for a research cooperation to perform the in vitro and in vivo pre-clinical validation.
  • Description:
    Current medicine is very focused on the development of new therapies against multi-drug resistant (MDR) bacterial infections. The World Health Organisation (WHO) expects that in 2050 infectious diseases caused by deadly bacteria will be the principal cause of mortality in Europe.
    Spanish SME focused on the development of biodegradable polyurethane micro and nanocapsules for industrial, personal care and pharmaceuticals sectors specializes in the synthesis of nanopolymeric entities to selectively deliver chemical or therapeutic entities.
    After more than 10 years of collaborative research, the company has introduced a novel technological platform in the field of Drug Delivery Systems (DDS).
    This innovative technology could be very conveniently implemented in bacterial infections therapy. It is able to create authentic all-in-one nanosystems with biodegradability, targeting, penetrating and multi drug encapsulation properties.
    With this multifunctional DDS, it could be possible to enhance antibacterial drugs pharmacokinetics and efficacy in intravenous, inhalation, oral or topic administration. Similarly, it would be possible to reduce the therapeutic concentration of the drug, thus lowering its side effects.
    The SME wants to develop nanoencapsulated systems using well-known antimicrobial-drugs, with difficulties to overcome adaptive resistance in one of the deathliest opportunistic pathogen: Pseudomonas Aeruginosa. Specially, carbapenem-resistant Pseudomonas Aeruginosa has been raised at critical level in WHO’s rank for bacterial infections for which are needed novel antibiotic therapies. Pseudomonas Aeruginosa is a Gram-negative bacterium which commonly causes several nosocomial and life-threatening infections in patients with cystic fibrosis, burn wounds and pulmonary infections. This is a major cause of hospital-acquired infections in patients.
    In this context, nanoencapsulation could provide solutions to overcome some barriers in the efficacy of antimicrobial-drugs.
    Based on the company’s previous experience with biodegradable polyurethane/polyurea nanocapsules, they can contribute to avoid most of the anti-microbial resistance mechanisms developed by Pseudomonas Aeruginosa. Once encapsulated, the antimicrobial-drug would not be affected by bacterial-released enzymes that would degrade or restrain it. Moreover, external media close to the bacterial cells neither would interact with the drug. This fact allows us to put unstable antimicrobial-drugs in direct contact with the active infection bacteria.
    Additionally, for combination therapies treating a broader spectrum of bacterial infections, it is possible to co-encapsulate two or more drugs (hydrophobic-hydrophobic, hydrophilic-hydrophilic or hydrophobic-hydrophilic drugs combination).
    Through nanocapsule shell functionalization with biofilm-targeted and/or biofilm-penetrating motifs, nanocapsules could penetrate through biofilms secretions, thus driving drugs onto inaccessible bacterial colonies.
    The Spanish company is willing to lead a powerful consortium based on innovative encapsulated antibiotic drugs that can potentially disrupt the way we treat infections. Thus medical and biological partners with a deep understanding of antimicrobial drugs and their resistance mechanisms to perform advanced preclinical assays are sought.
    The project will encompass from lab developing of nanoparticles to testing them in preclinical analysis in vitro as well as in vivo. The outcome of the project would be to patent the product, create a spin-off and obtain funding to perform clinical phases 2 years after the project finalization. Partners who want to be part of this collaboration must come from the eligible countries considered in Eurostars’ bases and they have to check the finance method with their National Project Coordinator.
    Deadline of the call: 12th September 2019
    Deadline for EOI: 31st May 2019
Partner Sought
  • Type of Partnership Considered:
    Research cooperation agreement
  • Technical Specification or Expertise Sought:

    The Spanish company as a consortium leader seeks research agreements with hospitals groups, research entities or biotech and/or pharmaceutical enterprises which are also interested in this medical field. The SME offers all of its know-how and infrastructure on the synthesis of polyurethane nanocapsules and its physical and chemical characterization and evaluation, and the partners should perform the in vitro and in vivo pre-clinical tests.
    Specifically, the SME is looking for partners with experience in:
    - In vitro tests to verify the drug selectivity and delivery to the chosen bacteria, the nanocapsules efficiency and the interaction with biofilms.
    - In vivo assays to test the biodistribution and efficacy.

    SME 11-50,University,R&D Institution,SME <10,SME 51-250

Organisation
  • Development stage:
    Proposal under development
  • IPR Status:
  • Market keywords:
    Microbiology
    Micro- and Nanotechnology related to Biological sciences
    Drug delivery and other equipment
    Other clinical medicine
    Pharmaceuticals/fine chemicals
  • Technology keywords:
    Micro- and Nanotechnology
    Pharmaceutical Products / Drugs
    Virus, Virology/Antibiotics/Bacteriology
    Microbiology
    Micro- and Nanotechnology related to Biological sciences
  • NACE keywords:
  • Advantages and Innovations:
Client
  • Type and Size of Organisation:
    Industry SME 11-49
  • Already Engaged in Trans-National Cooperation
    Ja
  • Year Established:
    0
  • Turnover:
  • Country of origin:
    Spain
  • Languages spoken
    • English
    • Spanish
Program